The Story of ResMed

The Recurring Therapy

ResMed (RMD) manufactures continuous positive airway pressure devices — CPAP machines — and the masks, cushions, tubing, and accessories that accompany them. The company serves an estimated one billion people worldwide who suffer from obstructive sleep apnea, a condition where the airway collapses during sleep, interrupting breathing and degrading health over time. The structural significance of ResMed is not the device itself but the system of recurring consumption it creates once a patient begins therapy.

Sleep apnea occupies an unusual position in medicine. It is extraordinarily common, severely underdiagnosed, and requires ongoing mechanical intervention rather than a pharmaceutical cure. There is no pill that holds an airway open during sleep. The condition does not resolve. Patients who begin CPAP therapy typically use it every night for the rest of their lives. This permanence is the foundation of ResMed's structural position.

Understanding ResMed's arc reveals how a company can build durable competitive advantages not through patents or brand alone but through the interaction of consumable economics, data accumulation, regulatory entrenchment, and clinical workflow integration. Each reinforces the others in ways that are difficult to replicate piecemeal.

The Long-Term Arc

ResMed's development follows a progression from device manufacturer to connected health platform, with each phase deepening the structural advantages established in the prior one.

How did ResMed build its early installed base (1989–2005)?

ResMed was founded in 1989 by Peter Farrell, emerging from research at the University of Sydney. The early years focused on building a better CPAP device — quieter, more comfortable, with improved airflow algorithms. The fundamental challenge was patient compliance. CPAP therapy is effective but uncomfortable. Many patients abandon treatment because the mask is intrusive, the air pressure feels unnatural, and the device is noisy. ResMed invested heavily in reducing these friction points, understanding that the installed base of active users — not just units sold — was the asset that mattered.

During this period, ResMed established the consumable replacement cycle that would become its structural engine. CPAP masks degrade with nightly use. Silicone cushions lose their seal. Tubing accumulates moisture and bacteria. Insurance guidelines in the United States — the largest market — established replacement schedules: new masks every three months, cushions every two weeks to a month, tubing every three months. Each active CPAP user generates a continuous stream of consumable demand. The installed base became a recurring revenue annuity, growing with every new patient who began therapy and never fully diminishing because the condition is permanent.

How did wireless connectivity transform ResMed's devices (2005–2017)?

ResMed's second structural phase began with the integration of wireless connectivity into its devices. The company embedded cellular modems and later Bluetooth into CPAP machines, enabling automatic transmission of usage data — hours of use, mask leak rates, apnea-hypopnea index, and breathing patterns — to cloud platforms accessible by clinicians, insurers, and patients. This was not a software add-on. It was a fundamental transformation of the company's competitive position.

The data moat began compounding. By the mid-2010s, ResMed had collected billions of nights of sleep data from millions of connected devices. This dataset has no equivalent. No competitor, no academic institution, no government health system possesses anything comparable. The data enables ResMed to refine its algorithms for auto-titrating pressure, predict compliance failures before they happen, and demonstrate therapy effectiveness to payers. Data became a structural asset that grows more valuable with every night a patient sleeps — a compounding advantage with no diminishing returns in sight.

How did ResMed expand from device maker to care platform (2017–Present)?

ResMed's third phase involves expansion from device manufacturer to care management platform. The acquisitions of Brightree and MatrixCare gave the company software platforms for home medical equipment providers and post-acute care facilities. These platforms manage billing, resupply logistics, and patient engagement — embedding ResMed into the operational infrastructure of the distribution channel, not just the product catalog.

In June 2021, Philips — ResMed's primary competitor in the CPAP duopoly — issued a massive recall of its DreamStation devices due to degraded sound abatement foam that could release particles and gases into the airway.

The recall affected an estimated 5.5 million devices globally. Philips effectively exited the market for over two years while redesigning its product. This was a structural windfall for ResMed of extraordinary magnitude. New patient starts, replacement devices for recalled Philips units, and the consumable streams attached to those patients flowed almost entirely to ResMed. The duopoly temporarily became a near-monopoly, and the patients acquired during this period represent years of future consumable revenue.

Structural Patterns

Consumable Annuity Economics — The CPAP therapy model generates recurring revenue from mask, cushion, and tubing replacements on insurance-dictated schedules. The installed base of active users is the true asset, not device unit sales.
Data Moat Through Connected Devices — Billions of nights of sleep data collected from millions of cloud-connected devices create an informational advantage that no competitor can replicate without equivalent scale and time.
Regulatory and Clinical Stickiness — Prescribers develop familiarity with specific device interfaces and data platforms. Insurance formularies and durable medical equipment providers build workflows around ResMed's systems. Switching costs are distributed across the entire care ecosystem, not concentrated in any single actor.
Duopoly Structure With Asymmetric Advantage — The CPAP market has historically been a duopoly between ResMed and Philips. Philips' recall structurally weakened its position, shifting share and installed base toward ResMed in a way that persists through the consumable replacement cycle.
Underdiagnosis as a Growth Reservoir — An estimated 80% of moderate to severe sleep apnea cases remain undiagnosed. The addressable market expands not through product innovation but through diagnostic penetration — a secular tailwind independent of competitive dynamics.
Platform Embedding Through Software — Acquisitions of Brightree and MatrixCare embed ResMed into the billing and logistics infrastructure of home medical equipment providers, creating switching costs that extend beyond the device itself.

Key Turning Points

The integration of wireless connectivity into CPAP devices — beginning around 2005 and reaching full deployment by 2014 — was the most consequential structural decision in ResMed's history. Before connectivity, a CPAP machine was a durable medical device that sat on a nightstand and generated replacement mask revenue. After connectivity, it became a data collection node in a cloud platform that could demonstrate compliance to insurers, guide clinical interventions, optimize therapy algorithms, and predict patient behavior. This transformation converted a hardware business into a hardware-plus-data business, and the data advantage compounds with every additional user-night recorded.

The Philips recall in 2021 was not a decision ResMed made, but its effects on the competitive structure were profound. Patients and providers who switched to ResMed during the recall period are now embedded in ResMed's ecosystem — using ResMed masks, connected to ResMed's myAir patient app, generating data in ResMed's cloud, and ordering replacement consumables through channels optimized for ResMed products. The recall did not just shift quarterly market share. It shifted the installed base, and the installed base is the structural asset that generates years of downstream revenue.

The acquisition of Brightree in 2016 and MatrixCare in 2019 marked the transition from device company to platform company. By owning the software that home medical equipment providers use to manage their businesses — inventory, billing, resupply automation, patient outreach — ResMed made itself difficult to remove from the distribution channel. A competitor would need to displace not just the device but the operational software that surrounds it.

Risks and Fragilities

The most discussed structural risk to ResMed is GLP-1 receptor agonist medications — drugs like semaglutide (Ozempic, Wegovy) that produce significant weight loss. Obesity is a major risk factor for obstructive sleep apnea, and weight loss can reduce or eliminate symptoms in some patients. If GLP-1 adoption becomes widespread among the obese population, the inflow of new CPAP patients could slow, and some existing patients might discontinue therapy. The magnitude of this effect remains uncertain. Sleep apnea has causes beyond obesity — craniofacial anatomy, aging, and neuromuscular factors all contribute — and long-term GLP-1 adherence data is limited. But the risk is structurally real and represents the first credible threat to the assumption that the CPAP-dependent population only grows.

Reimbursement policy is a persistent fragility. CPAP therapy in the United States depends heavily on Medicare and private insurance coverage for both devices and consumables. Changes to replacement schedules, coverage criteria, or reimbursement rates could compress the consumable revenue stream. Competitive bidding programs have already pressured pricing in some categories. The regulatory environment that enables the consumable annuity can also constrain it.

Concentration in the sleep apnea market creates exposure to technological disruption. Oral appliance therapy, hypoglossal nerve stimulation devices like Inspire Medical's implant, and potential pharmaceutical interventions all represent alternative treatment modalities. None currently matches CPAP's efficacy for moderate to severe cases, but the therapeutic landscape is not static. ResMed's structural position depends on CPAP remaining the standard of care — a position that is currently strong but not guaranteed indefinitely.

What Investors Can Learn

Installed base economics can be more valuable than unit sales — When a product creates a permanent user who generates recurring consumable demand, the cumulative installed base becomes the primary driver of long-term revenue, not the pace of new device sales.
Data moats compound with time and scale — Proprietary datasets that grow automatically through product usage create advantages that widen over time. Competitors cannot purchase or shortcut the accumulation of billions of data points.
Competitor failures can create structural windfalls — The Philips recall demonstrates that competitive positions can shift dramatically through events outside a company's control. The durability of the shift depends on whether the installed base transfers permanently.
Ecosystem embedding creates layered switching costs — When a company's products are integrated into clinical workflows, insurance processes, and distribution channel software, switching costs multiply across the ecosystem rather than residing in any single relationship.
Underdiagnosis is a structural growth reservoir — Markets where the majority of the addressable population has not yet been identified offer secular growth independent of market share competition. The constraint is diagnosis, not demand.

Inside CompanyGraph

View this perspective inside CompanyGraph.